Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study.
In the present study we aimed to demonstrate the efficacy of short-term pretreatment with finasteride in patients undergoing transurethral resection of the prostate (TUR-P). For this purpose 40 patients with BPH, who were candidates for TUR-P, were randomized into two groups. The first group (n=20) received 5 mg finasteride/day for 4 weeks prior to surgery and the second group (n=20) remained as the control. Patients who underwent prior prostate or urethral surgery and had a diagnosis of prostate cancer or chronic renal failure, patients who received finasteride, aspirin, coumadin or similar anticoagulant drugs prior to surgery and patients who had capsule perforations or open sinuses during the surgery were excluded from the study. All patients had a normal digital rectal examination and PSA values less than 4 ng/ml. As we look at the results there was no statistically significant difference between the finasteride group and control group regarding age, IPSS, PSA, prostate volumes, preoperative serum hemoglobin, hematocrit values and mean operating times and used irrigating fluids. The total amount of bleeding and bleeding per gram resected tissue were significantly lower in the finasteride group regardless of prostate volume. Furthermore the decrease in the hemoglobin and hematocrit values was higher in the control group. As a conclusion four weeks of finasteride pretreatment provided a significant decrease in peroperative bleeding regardless of prostate volume without any major side effects.
Department of Urology, Ankara Numune Education and Research Hospital, Ankara, Turkey. leventozdal@hotmail.com
O L
OL
Ozdal
C
C
Ozden
K
K
Benli
S
S
Gökkaya
S
S
Bulut
A
A
Memiş
D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use*; D006454:Hemoglobins / Q000737:chemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D051437:Renal Insufficiency / Q000188:drug therapy / Q000601:surgery; D012306:Risk; D013997:Time Factors; D020728:Transurethral Resection of Prostate / Q000379:methods*; D014521:Urethra / Q000473:pathology / Q000601:surgery; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D006454:Hemoglobins; D018120:Finasteride; D014859:Warfarin; D017430:Prostate-Specific Antigen; D001241:Aspirin